Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)
Status:
Completed
Trial end date:
2021-01-05
Target enrollment:
Participant gender:
Summary
People infected with HIV often have cognitive dysfunction even if they are on antiretroviral
therapy (ART) and have undetectable viral loads. The purpose of this study is to evaluate if
the addition of maraviroc (MVC) and dolutegravir (DTG) (which are two antiretroviral [ARV]
medications) to participants' existing ART regimens will improve participants' neurocognitive
performance.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)